RE:RE:RE:RE:Did anyone postMykndrsn wrote: Clarus was a buyer on Thursday despite the unprofessional outburst from Atkinson. I'm certain his clients and employer were not impressed by his inability to contain himself on a live feed.
I'm not sure about that as his statement was one of the most damaging aspects of the CC and I wish he hadn't said it - call a spade a spade - its Atkinson's job to identify and point his investors to the brightest options on the stock market - in SZ's case they waited over 6 months for the big news on the Aristotle roll out package - his disappointment comment along with future comments on that rollout will be carefully assessed by his investors. He has provided the main analyst coverage over the past year with some positive articles on the possibility of a billion dollar market cap - all of this on the back of Aristotle's future - furthermore Clarus has supported Tripp's pp and backed the company heavily via the purchase of shares. This has all supported the sp. The near 3 months of silence obviously heightened his expectations along with everyone else - who would the big partners/affiliates be - Atkinson and the rest of us dreamed about Mass National Hospital network, Rexall, EXAS, GRAIL etc. etc. but in the end the turth is that we got a very small medical service with limited clinics in the US.
"That's why our 20 plus people at Care Oncology works so hard every day." Clarus's next overview of SZLS will be important - clearly Atkinson hoped that any partnership deal would see a bigger player investing in SZ rather than the opposite with SZ further dilluting and buying someone out for $40 million via a massive share deal.
I am still hopeful that Tripp will pull a rabbit from the hat and announce a big work place employer or contract elsewhere to turn the tide - however in the short term Clarus is a concern......